RT Journal Article
T1 Crambescidin-816 Acts as a Fungicidal with More Potency than Crambescidin-800 and -830, Inducing Cell Cycle Arrest, Increased Cell Size and Apoptosis in Saccharomyces cerevisiae
A1 Rubiolo Gaytán, Juan Andrés
A1 Ternon, Eva
A1 López Alonso, Henar
A1 Thomas, Olivier P.
A1 Vega Lisi, Félix Víctor
A1 Rodríguez Vieytes, Mercedes
A1 Botana López, Luis Miguel
K1 Crambescidine-816
K1 Antifungal
K1 Cell cycle arrest
K1 Apoptosis
AB In this paper, we show the effect of crambescidin-816, -800, and -830 on Saccharomyces cerevisiae viability. We determined that, of the three molecules tested, crambescidin-816 was the most potent. Based on this result, we continued by determining the effect of crambescidin-816 on the cell cycle of this yeast. The compound induced cell cycle arrest in G2/M followed by an increase in cell DNA content and size. When the type of cell death was analyzed, we observed that crambescidin-816 induced apoptosis. The antifungal effect indicates that crambescidins, and mostly crambescidin-816, could serve as a lead compound to fight fungal infections
PB MDPI
YR 2013
FD 2013
LK http://hdl.handle.net/10347/23606
UL http://hdl.handle.net/10347/23606
LA eng
NO Rubiolo, J.A.; Ternon, E.; López-Alonso, H.; Thomas, O.P.; Vega, F.V.; Vieytes, M.R.; Botana, L.M. Crambescidin-816 Acts as a Fungicidal with More Potency than Crambescidin-800 and -830, Inducing Cell Cycle Arrest, Increased Cell Size and Apoptosis in Saccharomyces cerevisiae. Mar. Drugs 2013, 11, 4419-4434
NO The research leading to these results has received funding from the following FEDER cofunded-grants: From Ministerio de Ciencia y Tecnología, Spain: AGL2009-13581-CO2-01, AGL2012-40485-CO2-01. From Xunta de Galicia, Spain: 10PXIB261254 PR. From the European Union’s Seventh Framework Programme managed by REA—Research Executive Agency (FP7/2007-2013) under grant agreement Nos. 211326—CP (CONffIDENCE), 265896 BAMMBO, 265409 µAQUA, and 262649 BEADS, 315285 Ciguatools and 312184 PharmaSea. From the Atlantic Area Programme (Interreg IVB Trans-national): 2009-1/117 Pharmatlantic
DS Minerva
RD 24 abr 2026